The roadshow begins July 14–15 at the Leerink Partners Therapeutics Forum in Boston, where CEO Erik Lundgren and his team, including President Jason Tardio and Chief Medical Officer Dr. Michael A. Panzara, will hold one-on-one meetings. This will be followed by a fireside chat on July 16 at the B. Riley Securities Mind, Muscle & Vision Summit, also in Boston. The circuit concludes on July 23 at the LifeSci Capital SF Biotech Forum in San Francisco.

These appearances arrive as the company nears a critical milestone for its primary development program, vidofludimus calcium (IMU-838). The drug, which targets relapsing multiple sclerosis through a unique combination of neuroprotective and anti-inflammatory mechanisms, is slated for top-line data results by the end of 2026. Beyond the lead candidate, the company is actively expanding its pipeline with earlier-stage programs like IMU-856 and IMU-381, designed to broaden their footprint in the autoimmune and neurodegenerative disease markets.